Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Rani Therapeutics Holdings (RANI) Equity Average (2021 - 2025)

Rani Therapeutics Holdings has reported Equity Average over the past 5 years, most recently at $16.8 million for Q4 2025.

  • Quarterly results put Equity Average at $16.8 million for Q4 2025, up 263.1% from a year ago — trailing twelve months through Dec 2025 was $16.8 million (up 263.1% YoY), and the annual figure for FY2025 was $22.5 million, up 55.53%.
  • Equity Average for Q4 2025 was $16.8 million at Rani Therapeutics Holdings, up from -$8.5 million in the prior quarter.
  • Over the last five years, Equity Average for RANI hit a ceiling of $126.6 million in Q4 2021 and a floor of -$121.1 million in Q2 2021.
  • Median Equity Average over the past 5 years was $18.4 million (2024), compared with a mean of $26.1 million.
  • Biggest five-year swings in Equity Average: skyrocketed 2205.96% in 2022 and later crashed 250.23% in 2025.
  • Rani Therapeutics Holdings' Equity Average stood at $126.6 million in 2021, then plummeted by 36.59% to $80.3 million in 2022, then plummeted by 62.48% to $30.1 million in 2023, then crashed by 84.62% to $4.6 million in 2024, then skyrocketed by 263.1% to $16.8 million in 2025.
  • The last three reported values for Equity Average were $16.8 million (Q4 2025), -$8.5 million (Q3 2025), and -$7.3 million (Q2 2025) per Business Quant data.